BioMerieux announces acquisition of Astute Medical

BioMerieux has announced the acquisition of fellow life science company Astute Medical, with which it has collaborated since 2015.

Astute Medical provides diagnostic solutions for high-risk medical conditions and diseases through the identification and validation of protein biomarkers, including Nephrocheck, a test for the early risk assessment of acute kidney injuries.

The company granted BioMerieux a licence to develop and market the Nephrocheck test for the Vidas automated immunoassay system in 2015, and BioMerieux has served as a licensed distributor for the test with Astute on the Astute140 Meter in the US since 2017.

The $90 million (GBP 63.77 million) deal will also give BioMerieux access to the other promising biomarkers in the Astute pipeline, while it will also work with Astute's current licence and distribution partners to commercialise Nephrocheck worldwide.

Alexandre Merieux, chairman and chief executive officer of BioMerieux, said: "The Nephrocheck test developed by Astute perfectly fits BioMerieux's strategy to differentiate Vidas through proprietary markers, and to provide our customers with innovative and high-medical-value diagnostic solutions for improved patient care."

With over 20 years of experience within the science market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current science roles we have available, you can search for the latest job roles, register your details, or contact the team today.